Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
Clete A Kushida, Colin M Shapiro, Thomas Roth, Michael J Thorpy, Bruce C Corser, Akinyemi O Ajayi, Russell Rosenberg, Asim Roy, David Seiden, Jordan Dubow, Yves Dauvilliers, Clete A Kushida, Colin M Shapiro, Thomas Roth, Michael J Thorpy, Bruce C Corser, Akinyemi O Ajayi, Russell Rosenberg, Asim Roy, David Seiden, Jordan Dubow, Yves Dauvilliers
Abstract
Study objectives: To assess the efficacy and safety of FT218, a novel once-nightly formulation of sodium oxybate (ON-SXB), in patients with narcolepsy in the phase 3 REST-ON trial.
Methods: Narcolepsy patients aged ≥16 years were randomized 1:1 to uptitration of ON-SXB (4.5, 6, 7.5, and 9 g) or placebo. Three coprimary endpoints were change from baseline in mean sleep latency on the Maintenance of Wakefulness Test, Clinical Global Impression-Improvement rating, and weekly cataplexy attacks at 9, 7.5, and 6 g. Secondary endpoints included change from baseline on the Epworth Sleepiness Scale. Safety included adverse drug reactions and clinical laboratory assessments.
Results: In total, 222 patients were randomized; 212 received ≥1 dose of ON-SXB (n = 107) or placebo (n = 105). For the three coprimary endpoints and Epworth Sleepiness Scale, all three doses of ON-SXB demonstrated clinically meaningful, statistically significant improvement versus placebo (all p < 0.001). For ON-SXB 9 g versus placebo, increase in mean sleep latency was 10.8 versus 4.7 min (Least squares mean difference, LSMD [95% CI], 6.13 [3.52 to 8.75]), 72.0% versus 31.6% were rated much/very much improved on Clinical Global Impression-Improvement (OR [95% CI], 5.56 [2.76 to 11.23]), change in mean weekly number of cataplexy attacks was -11.5 versus -4.9 (LSMD [95% CI], -6.65 [-9.32 to -3.98]), and change in Epworth Sleepiness Scale was -6.5 and -2.7 (LSMD [95% CI], -6.52 [-5.47 to -2.26]). Common adverse reactions included nausea, vomiting, headache, dizziness, and enuresis.
Conclusions: ON-SXB significantly improved narcolepsy symptoms; its safety profile was consistent with SXB. ON-SXB conferred efficacy with a clearly beneficial single nighttime dose.
Clinical trial registration: ClinicalTrials.gov: NCT02720744, https://ichgcp.net/clinical-trials-registry/NCT02720744.
Keywords: NT1/NT2; modified release; narcolepsy; once-nightly; safety; sodium oxybate.
© Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society.
Figures
References
- Kornum BR, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3(1):16100.
- Dauvilliers Y, et al. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499–511.
- Longstreth WT Jr, et al. The epidemiology of narcolepsy. Sleep. 2007;30(1):13–26. doi:10.1093/sleep/30.1.13.
- Daniels E, et al. Health-related quality of life in narcolepsy. J Sleep Res. 2001;10(1):75–81.
- Weaver TE, et al. Relationship between sleep efficacy endpoints and measures of functional status and health-related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness. J Sleep Res. 2021;30(3):e13210.
- Ingravallo F, et al. The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med. 2012;13(10):1293–1300.
- Dauvilliers Y, et al. Psychological health in central hypersomnias: the French Harmony study. J Neurol Neurosurg Psychiatry. 2009;80(6):636–641.
- Center for Drug Evaluation and Research (CDER). The Voice of the Patient: Narcolepsy. US Food and Drug Administration; 2014.
- Bassetti CLA, et al. Narcolepsy – clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019;15(9):519–539.
- Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654–2662.
- Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34(1):9–27.
- Thorpy MJ, et al. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16(1):9–18.
- Morgenthaler TI, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–1711. doi:10.1093/sleep/30.12.1705.
- Barateau L, et al. Treatment options for narcolepsy. CNS Drugs. 2016;30(5):369–379.
- Jazz Pharmaceuticals. Xywav (Calcium, Magnesium, Potassium, and Sodium Oxybates). Full Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals; 2020.
- Jazz Pharmaceuticals. Xyrem (Sodium Oxybate Oral Solution, CIII). Full Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals; 2020.
- Ágh T, et al. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82(4):328–334.
- Medic G, et al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2013;9:119–131.
- Nachega JB, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297–1307.
- Stang P, et al. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Am J Ther. 2007;14(3):241–246.
- Stang P, et al. Better patient persistence with once-daily bupropion compared with twice-daily bupropion. Am J Ther. 2007;14(1):20–24.
- Pfeiffer PN, et al. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv. 2008;59(10):1207–1210.
- Saini SD, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22–e33.
- Srivastava K, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419–434.
- Pérez-Carbonell L, et al. Adherence to wakefulness promoting medication in patients with narcolepsy. Sleep Med. 2020;70:50–54.
- Roth T, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9(9):955–965.
- Mayer G, et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep. 2018;41(9). doi:10.1093/sleep/zsy128.
- Bogan RK, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3). doi:10.1093/sleep/zsaa206.
- Seiden D, et al. Pharmacokinetics of FT218, a once-nightly sodium oxybate formulation in healthy adults. Clin Ther. 2021;43(4):672.e1–672.e14.
- Black J, et al. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6(6):596–602.
- American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
- Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540–545. doi:10.1093/sleep/14.6.540.
- U. S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42–49. doi:10.1093/sleep/25.1.42.
- Maski K, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021; epub ahead of print.
- Maski K, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021; epub ahead of print.
- Roy A, et al. Efficacy of FT218, a once-nightly sodium oxybate formulation, by narcolepsy subtype: a post hoc analysis from the REST-ON study. Sleep. 2021;44(Suppl 2). doi:10.1093/sleep/zsab072.490.
- Roy A, et al. Efficacy of FT218, a once-nightly sodium oxybate formulation, by stimulant use: a post hoc analysis from the REST-ON study. Sleep. 2021;44(Suppl 2). doi:10.1093/sleep/zsab072.491.
- Black J, et al. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–946. doi:10.1093/sleep/29.7.939.
- Seiden D, et al. The pharmacokinetic adverse event relationship for FT218, a once-nightly sodium oxybate formulation. Sleep. 2020;43(Suppl 1). doi:10.1093/sleep/zsaa056.739.
- Wheless JW, et al. A clinician’s guide to oral extended-release drug delivery systems in epilepsy. J Pediatr Pharmacol Ther. 2018;23(4):277–292.
- Wertheimer AI, et al. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther. 2005;22(6):559–577.
- U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Approval package for application number: NDA 21-196/S-019. Available at: . Accessed July 1, 2021.
- Roth T, et al. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res. 2017;26(4):407–414.
- Avadel Pharmaceuticals. Avadel Pharmaceuticals announces FDA acceptance of new drug application for FT218 in adults with narcolepsy for the treatment of excessive daytime sleepiness and cataplexy. Available at: . Accessed April 21, 2021.
Source: PubMed